局部注射维生素D3治疗皮肤疣:一项随机、双盲、安慰剂对照试验

IF 2.5 Q1 PRIMARY HEALTH CARE
Stephen P Merry, David N Brennan, Michelle J Duvall, Joseph B Stanek, Erin K O'Dowd, Tom D Thacher
{"title":"局部注射维生素D3治疗皮肤疣:一项随机、双盲、安慰剂对照试验","authors":"Stephen P Merry, David N Brennan, Michelle J Duvall, Joseph B Stanek, Erin K O'Dowd, Tom D Thacher","doi":"10.1177/21501319251365853","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Treatment of cutaneous warts with intralesional vitamin D3 has demonstrated promising results in over 35 studies with methodological limitations.</p><p><strong>Methods: </strong>We conducted a randomized, double-blind, placebo-controlled trial in our primary care procedure clinic of intralesional vitamin D3 12 000 IU vs placebo in cutaneous warts every 4 weeks up to 3 times. Warts were assessed 4, 8, 12, and 24 weeks after the initial injection. The primary outcome was complete wart resolution. Reduction in wart size was a secondary outcome.</p><p><strong>Results: </strong>Between October 2020 and April 2023, we enrolled 77 participants with 1 or more cutaneous warts (41 and 36 in vitamin D3 and placebo groups, respectively) with untreated (32%) and recalcitrant (69%) warts. At 24 weeks, the index wart had resolved in 12 (30%) of vitamin D3 and 10 (31%) placebo participants. Treatment with vitamin D3 had no effect on wart surface area in an adjusted model nor wart resolution in analysis adjusted for baseline wart size, multiple warts, and the vehicle (OR 0.31 [95% CI] 0.01-10.3; <i>P</i> = 0.51).</p><p><strong>Conclusions: </strong>These results demonstrate a lack of benefit of intralesional vitamin D3 in cutaneous warts.(ClinicalTrials.gov number NCT04278573).</p>","PeriodicalId":46723,"journal":{"name":"Journal of Primary Care and Community Health","volume":"16 ","pages":"21501319251365853"},"PeriodicalIF":2.5000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12375156/pdf/","citationCount":"0","resultStr":"{\"title\":\"Intralesional Injection of Vitamin D3 for Treatment of Cutaneous Warts: A Randomized, Double-Blind, Placebo-Controlled Trial.\",\"authors\":\"Stephen P Merry, David N Brennan, Michelle J Duvall, Joseph B Stanek, Erin K O'Dowd, Tom D Thacher\",\"doi\":\"10.1177/21501319251365853\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Treatment of cutaneous warts with intralesional vitamin D3 has demonstrated promising results in over 35 studies with methodological limitations.</p><p><strong>Methods: </strong>We conducted a randomized, double-blind, placebo-controlled trial in our primary care procedure clinic of intralesional vitamin D3 12 000 IU vs placebo in cutaneous warts every 4 weeks up to 3 times. Warts were assessed 4, 8, 12, and 24 weeks after the initial injection. The primary outcome was complete wart resolution. Reduction in wart size was a secondary outcome.</p><p><strong>Results: </strong>Between October 2020 and April 2023, we enrolled 77 participants with 1 or more cutaneous warts (41 and 36 in vitamin D3 and placebo groups, respectively) with untreated (32%) and recalcitrant (69%) warts. At 24 weeks, the index wart had resolved in 12 (30%) of vitamin D3 and 10 (31%) placebo participants. Treatment with vitamin D3 had no effect on wart surface area in an adjusted model nor wart resolution in analysis adjusted for baseline wart size, multiple warts, and the vehicle (OR 0.31 [95% CI] 0.01-10.3; <i>P</i> = 0.51).</p><p><strong>Conclusions: </strong>These results demonstrate a lack of benefit of intralesional vitamin D3 in cutaneous warts.(ClinicalTrials.gov number NCT04278573).</p>\",\"PeriodicalId\":46723,\"journal\":{\"name\":\"Journal of Primary Care and Community Health\",\"volume\":\"16 \",\"pages\":\"21501319251365853\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12375156/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Primary Care and Community Health\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/21501319251365853\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/23 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"PRIMARY HEALTH CARE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Primary Care and Community Health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/21501319251365853","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/23 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PRIMARY HEALTH CARE","Score":null,"Total":0}
引用次数: 0

摘要

在超过35项研究中,用局部维生素D3治疗皮肤疣已经显示出有希望的结果,但存在方法学上的局限性。方法:我们在我们的初级保健程序诊所进行了一项随机、双盲、安慰剂对照试验,每4周对皮肤疣进行局部注射维生素D3 12 000 IU和安慰剂,最多3次。在首次注射后4、8、12和24周评估疣。主要结果是疣完全消退。减少疣体大小是次要结果。结果:在2020年10月至2023年4月期间,我们招募了77名患有1个或更多皮肤疣的参与者(维生素D3组和安慰剂组分别为41人和36人),未治疗(32%)和顽固性(69%)疣。在24周时,维生素D3组的12人(30%)和安慰剂组的10人(31%)的指数疣消失了。在调整后的模型中,维生素D3治疗对疣表面面积没有影响,在基线疣大小、多个疣和载体的分析中,对疣分辨率也没有影响(OR 0.31 [95% CI] 0.01-10.3; P = 0.51)。结论:这些结果表明局部注射维生素D3对皮肤疣缺乏益处(ClinicalTrials.gov编号NCT04278573)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Intralesional Injection of Vitamin D3 for Treatment of Cutaneous Warts: A Randomized, Double-Blind, Placebo-Controlled Trial.

Intralesional Injection of Vitamin D3 for Treatment of Cutaneous Warts: A Randomized, Double-Blind, Placebo-Controlled Trial.

Intralesional Injection of Vitamin D3 for Treatment of Cutaneous Warts: A Randomized, Double-Blind, Placebo-Controlled Trial.

Intralesional Injection of Vitamin D3 for Treatment of Cutaneous Warts: A Randomized, Double-Blind, Placebo-Controlled Trial.

Introduction: Treatment of cutaneous warts with intralesional vitamin D3 has demonstrated promising results in over 35 studies with methodological limitations.

Methods: We conducted a randomized, double-blind, placebo-controlled trial in our primary care procedure clinic of intralesional vitamin D3 12 000 IU vs placebo in cutaneous warts every 4 weeks up to 3 times. Warts were assessed 4, 8, 12, and 24 weeks after the initial injection. The primary outcome was complete wart resolution. Reduction in wart size was a secondary outcome.

Results: Between October 2020 and April 2023, we enrolled 77 participants with 1 or more cutaneous warts (41 and 36 in vitamin D3 and placebo groups, respectively) with untreated (32%) and recalcitrant (69%) warts. At 24 weeks, the index wart had resolved in 12 (30%) of vitamin D3 and 10 (31%) placebo participants. Treatment with vitamin D3 had no effect on wart surface area in an adjusted model nor wart resolution in analysis adjusted for baseline wart size, multiple warts, and the vehicle (OR 0.31 [95% CI] 0.01-10.3; P = 0.51).

Conclusions: These results demonstrate a lack of benefit of intralesional vitamin D3 in cutaneous warts.(ClinicalTrials.gov number NCT04278573).

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.80
自引率
2.80%
发文量
183
审稿时长
15 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信